clinical trial · NCT06292013
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company·phase3·active not recruiting·n = 17,300
Atherosclerotic Cardiovascular Disease (ASCVD)Elevated Lp(a)Lepodisiran SodiumPlacebo
brief summary
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin). Approximately 1700 additional participants will be enrolled in an addendum to explore Lp(a) lowering with an alternative dosing schema.
started
Mar 5, 2024
primary completion
Mar 1, 2029
completion
Mar 1, 2029
last updated
May 19, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event - ACCLAIM-Lp(a)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol